Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4276
Patriot National Bancorp
PNBK
$140M
| $196K | ﹤0.01% |
107,513
+35,052
| +48% | +$48.4K |
|
4277
EVI Industries
EVI
$195M
| $195K | ﹤0.01% |
7,900
+431
| +6% | +$10.7K |
|
4278
Inhibikase Therapeutics
IKT
$377M
| $194K | ﹤0.01% |
94,795
+9,217
| +11% | +$14.7K |
|
4279
Lifeway Foods
LWAY
$448M
| $194K | ﹤0.01% |
8,009
+659
| +9% | +$16.2K |
|
4280
FT Vest US Equity Buffer & Premium Income ETF September
XISE
$35.7M
| $194K | ﹤0.01% |
6,381
+641
| +11% | +$19.4K |
|
|
EWCZ
4281
DELISTED
European Wax Center
EWCZ
| $192K | ﹤0.01% |
53,398
+6,185
| +13% | +$23.1K |
|
|
PTRN
4282
Pattern Group Inc
PTRN
$3.96B
| $192K | ﹤0.01% |
16,652
+3,352
| +25% | +$48.8K |
|
|
SFBC
4283
Sound Financial Bancorp
SFBC
$119M
| $192K | ﹤0.01% |
4,402
+354
| +9% | +$15.8K |
|
|
KGEI
4284
Kolibri Global Energy
KGEI
$191M
| $192K | ﹤0.01% |
48,822
+4,423
| +10% | +$19.2K |
|
4285
Finance of America Companies
FOA
$203M
| $191K | ﹤0.01% |
7,907
+1,525
| +24% | +$34.7K |
|
4286
FT Vest US Equity Moderate Buffer ETF June
GJUN
$535M
| $191K | ﹤0.01% |
4,828
-346
| -7% | -$13.5K |
|
4287
2x Long VIX Futures ETF
UVIX
$204M
| $191K | ﹤0.01% |
1,674
+1,000
| +148% | +$183K |
|
4288
Finward Bancorp
FNWD
$196M
| $190K | ﹤0.01% |
5,403
+541
| +11% | +$19K |
|
4289
Algoma Steel
ASTL
$466M
| $190K | ﹤0.01% |
46,246
+45,877
| +12,433% | +$183K |
|
4290
TaskUs
TASK
$623M
| $189K | ﹤0.01% |
16,052
-1
| -0% | -$13 |
|
4291
Takeda Pharmaceutical
TAK
$55.5B
| $189K | ﹤0.01% |
12,137
+10,388
| +594% | +$149K |
|
4292
Kiniksa Pharmaceuticals
KNSA
$6.06B
| $189K | ﹤0.01% |
4,577
-2,776
| -38% | -$111K |
|
|
API
4293
Agora
API
$384M
| $187K | ﹤0.01% |
45,911
-7,000
| -13% | -$25.7K |
|
4294
Evolution Petroleum
EPM
$133M
| $187K | ﹤0.01% |
52,739
+5,121
| +11% | +$21.6K |
|
4295
Comp X International
CIX
$395M
| $186K | ﹤0.01% |
8,003
+245
| +3% | +$5.54K |
|
4296
Ondas Inc
ONDS
$5.57B
| $184K | ﹤0.01% |
18,829
+18,406
| +4,351% | +$148K |
|
4297
CALL
Shell
SHEL
$249B
| $184K | ﹤0.01% |
2,500
-350,100
| -99% | -$25.8M |
|
|
RPT
4298
Rithm Property Trust
RPT
$99.6M
| $184K | ﹤0.01% |
11,071
+1,690
| +18% | +$26K |
|
4299
Immix Biopharma
IMMX
$799M
| $183K | ﹤0.01% |
+35,000
| New | +$144K |
|
|
AOMR
4300
Angel Oak Mortgage REIT
AOMR
$208M
| $183K | ﹤0.01% |
21,239
+3,741
| +21% | +$33.5K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.